Related Experiment Video
Updated: Jul 15, 2026
14:19
Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction
Published on: October 14, 2016
Effects of perhexiline maleate on coronary flow distribution in the ischemic canine myocardium
Circulation
|July 1, 1976
Insights
Perhexiline maleate, administered intravenously, improved coronary blood flow and reduced myocardial oxygen consumption in dogs. The drug did not alter the threshold for left ventricular failure due to ischemia.
Area of Science:
- Cardiovascular Pharmacology
- Myocardial Metabolism
- Ischemic Heart Disease
Background:
- Coronary artery disease remains a leading cause of mortality.
- Understanding the effects of novel pharmacological agents on myocardial function is crucial for developing new treatments.
- Perhexiline maleate is a drug with known anti-anginal properties.
Purpose of the Study:
- To investigate the effects of intravenous perhexiline maleate on coronary hemodynamics and myocardial metabolism in a canine model.
- To determine if perhexiline maleate can preserve endocardial blood flow under conditions of fixed coronary flow.
- To assess the impact of perhexiline maleate on the threshold for ischemic-induced left ventricular failure.
Main Methods:
- Intravenous administration of perhexiline maleate in a canine model.
- Measurement of coronary diastolic pressure and coronary blood flow.
- Assessment of myocardial oxygen consumption and lactate uptake.
- Evaluation of the threshold for ischemic-induced left ventricular failure.
Main Results:
- Perhexiline maleate increased coronary diastolic pressure.
- The drug effectively redistributed coronary blood flow, preserving endocardial flow.
- Myocardial oxygen consumption was significantly reduced.
- Lactate uptake was enhanced by perhexiline maleate.
- No significant effect was observed on the threshold for ischemic-induced left ventricular failure.
Conclusions:
- Intravenous perhexiline maleate demonstrates beneficial effects on coronary hemodynamics and myocardial metabolism in a canine model.
- The drug's ability to preserve endocardial flow and reduce oxygen demand suggests potential therapeutic value in ischemic heart conditions.
- Further research is warranted to explore the clinical efficacy of perhexiline maleate in patients with coronary artery disease.
Abstract:
Intravenous perhexiline maleate in a canine preparation with fixed coronary flow increases coronary diastolic pressure. It also redistributes coronary flow so as to preserve endocardial flow. Myocardial oxygen consumption was reduced and lactate uptake enhanced by the drug. It had no effect upon the threshold for ischemic-induced left ventricular failure.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:26Imbalances in Cardiac Output
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
01:22Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...